• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AMTI

AMTI

Applied Molecular Transport Inc.

NASDAQHealthcareBiotechnologyUS

USD0.26

-0.01 (-3.13%)

Company Profile

CEO

Shawn M. Cross

IPO Date

2020-06-05

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.31

Prev. Close

$0.27

Day Low

$0.26

Day High

$0.31

52W Low

$0.13

52W High

$0.84

Market Cap

$0.01B

Volume

0.24M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

43.6%

Avg Negative

1.6%

Avg Neutral

54.8%

News Feed

Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress

GlobeNewsWire·7/9/2021·↑ positive

Applied Molecular Transport to Present at Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/26/2021·↑ positive

Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·4/6/2021·↑ positive

Applied Molecular Transport Stock Price Increased 44.44%: Why It Happened

Pulse2·4/2/2021·↑ positive

Applied Molecular Transport Stock Price Increased Over 25% Intraday: Why It Happened

Pulse2·4/1/2021·↑ positive

Applied Molecular Transport Announces Pricing of Public Offering of Common Stock

GlobeNewsWire·3/31/2021·↑ positive

Applied Molecular Transport Announces Proposed Public Offering of Common Stock

GlobeNewsWire·3/29/2021·↑ positive

Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewsWire·3/19/2021·↑ positive

Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference

GlobeNewsWire·3/9/2021·↑ positive

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

GlobeNewsWire·3/1/2021·↑ positive